What is DeepLife?
DeepLife is at the forefront of biological innovation, developing novel approaches to address diseases stemming from cellular perturbations. By leveraging state-of-the-art multi-omics data, machine learning, and systems engineering, the company aims to identify molecular triggers that restore cells to a healthy state. This sophisticated methodology addresses a long-standing challenge in biology: the iterative reconstruction of cell mechanisms to pinpoint causes of pathology.
How much funding has DeepLife raised?
DeepLife has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2024): $10M with participation from YZR Capital, Relyens en France, Groupe Prunay, and Beiersdorf
Key Investors in DeepLife
YZR Capital
YZR Capital is a venture capital firm likely focused on early-stage technology investments, given its presence in the funding round.
Relyens en France
Relyens en France, specializing in insurance for healthcare institutions, brings a unique perspective on risk management and patient safety, aligning with DeepLife's mission to combat disease.
Groupe Prunay
Groupe Prunay, with its diversified interests including venture capital, likely provides strategic financial guidance and investment expertise to support DeepLife's growth trajectory.
What's next for DeepLife?
The recent major enterprise-level funding positions DeepLife for significant scaling and further research and development. This strategic backing will likely accelerate the company's efforts to translate its cutting-edge computational biology into tangible therapeutic solutions. The focus will be on expanding its platform's capabilities and potentially initiating clinical trials to validate its disease-targeting strategies.
See full DeepLife company page
